Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study

发表于 5 天前

期刊：Journal of Clinical Oncology

文献作者：Lingfang Xia; Keqiang Zhang; Ying Tang; Guonan Zhang; Danbo Wang; Hanmei Lou; Naifu Liu; Hongping Zhang; Hongwei Chen; Ke Wang; Shuqing Wei; Li Wang; Kun Gao; Guiling Li; Huifeng Zhang; Yuanjing Hu; Weidong Zhao; Yunyan Zhang; Hong Zhu; An Lin; Jinwei Miao; Guohua Yu; Keqin Hua; Liangdan Tang; Ziling Liu; Bingzhong Zhang; Hongwei Li; Min Zheng; Xiaohong Wang; Fenghu Li; Xinfeng Yang; Huaijun Zhou; Bairong Xia; Xianfeng Zhou; Yuting Wang; Quanren Wang; Xiaohua Wu

出版日期：2025-8-20

DOI号：10.1200/jco-24-02495

下载链接：https://ascopubs.org/doi/pdfdirect/10.1200/JCO-24-02495

文献链接：https://doi.org/10.1200/jco-24-02495

当前文献来源于 American Society of Clinical Oncology (ASCO)。

备注信息：

发表于 5 天前

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ASCO] Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASCO] Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study 一键复制